Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Company Overview - Ultragenyx has seen its shares increase by approximately 9.6% over the past month, outperforming the S&P 500 [1] - The stock currently holds a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the coming months [4] Earnings Estimates - Fresh estimates for Ultragenyx have trended upward in the past month, although the magnitude of these revisions suggests a downward shift [2][4] - The company has a subpar Growth Score of D, a strong Momentum Score of A, and a poor Value Score of F, placing it in the bottom 20% for value investment strategy [3] Industry Performance - Ultragenyx is part of the Zacks Medical - Biomedical and Genetics industry, where Agios Pharmaceuticals has gained 20.6% over the past month [5] - Agios Pharmaceuticals reported revenues of $8.73 million for the last quarter, reflecting a year-over-year increase of 6.6% [6] - The expected loss per share for Agios Pharmaceuticals in the current quarter is projected at $1.74, which is a 3% decrease year-over-year [6]